News

Obesity surgery normalizes brain opioids

Researchers have revealed how obesity surgery recovers opioid neurotransmission in the brain.

 

Obesity is associated with lowered opioid receptor availability (top row) whereas availability of dopamine receptors is unchanged. Bariatric surgery recovers the opioid system but does not influence the dopamine system.

Finnish researchers found that obesity surgery and concomitant weight loss normalized brain’s opioid neurotransmission, which is involved in generating pleasurable sensations. Obesity surgery provides an effective means for rapid weight loss, and the research also shows that obesity surgery also normalizes brain circuits triggering pleasurable sensations when eating. The research outcome was recently published in Molecular Psychiatry journal.

– Our findings highlight how obesity is associated with brain-level molecular changes, and how weight loss influences appetite control at the molecular level in the brain. It is possible that the lack of brain’s opioid receptors predisposes the obese individuals to overeating to compensate decreased hedonic responses in this system. Obesity surgery however recovers this bias in the brain, tells Professor Lauri Nummenmaa from Aalto University.

– Because brain’s opioid system recovers following weight loss, it is likely that their lower levels in the obese are due to weight gain. Altered neurotransmitter levels are thus a consequence rather than a cause of obesity. These results help us to understand the mechanisms involved in weight loss and appetite, and provide new insight into behavioural and pharmacological treatment, continues researcher Henry Karlsson from Turku PET Centre.

Obesity is a great challenge to human health worldwide.

Obesity is a great challenge to human health worldwide because it is associated with serious medical conditions such as type 2 diabetes, coronary heart disease, and stroke. Obesity is also associated with alterations in the brain circuits that generate pleasurable sensations when eating, thus predisposing individuals to overeating.

The researchers measured availability of mu-opioid and type 2 dopamine receptors in normal-weight and obese individuals’ brains using positron emission tomography at the Turku PET Centre. The obese subjects underwent bariatric surgery, after which their brains were scanned again.

The research was funded by the Academy of Finland, Sigrid Juselius Foundation and The Finnish Diabetes Research Foundation.

Contact information:
Assistant professor Lauri Nummenmaa                     
Aalto University and Turku PET Centre                   
[email protected]                                        
tel. +358 50 431 9931            

Researcher Henry Karlsson
Turku PET Centre
tel. +358 40 728 3320
[email protected]

Original publication http://www.nature.com/mp/journal/vaop/ncurrent/full/mp2015153a.html

 

  • Published:
  • Updated:
Share
URL copied!

Read more news

Etualalla seisovan naisen taustalla abstrakti taustakuva, ja kuvan päällä keltaisella ohjelmointitekstiä
Press releases Published:

Finnish universities join forces to train 5G experts

FITech universities, and the University of Helsinki are using a million euros in funding from the Ministry of Education and Culture to launch expert training in 5G technology. The courses will be open to all, and free of charge. Training will also be available as a minor subject for university students.
QS-ranking tulos 2021
Press releases, Research & Art Published:

Aalto University’s Art & Design now ranked 6th in the world

Six of Aalto’s fields reached the top 100 in the prestigious QS ranking
Leffateatterin akustiikka tallennettiin erikoismikrofonilla. Kuva: Janne Riionheimo / Aalto-yliopisto
Press releases Published:

Cinema acoustics can modify substantially the soundscape of a movie

Carefully mixed music can sound stuffy or the clarity of speech may suffer, noticed researchers of Acoustics at Aalto University.
dox release from dna nanostructure aalto university
Press releases Published:

Researchers watch anti-cancer drug release from DNA nanostructures in real time

Findings provide insights into tunable drug delivery and new design paradigms of DNA-based drug-carriers